Citigroup’s CervoMed CRVO Stock Holding History

Citigroup’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06K	Buy	+664	New	+$2.34K	﹤0.01%	5374
2026 Q1	–	Sell	-1	Closed	-$8	–	6020
2025 Q4	$8	Sell	1 -15	-94%	-$121	﹤0.01%	5823
2025 Q3	$129	Sell	16 -945	-98%	-$8.11K	﹤0.01%	5793
2025 Q2	$6.04K	Sell	961 -2,884	-75%	-$24.6K	﹤0.01%	5257
2025 Q1	$35.2K	Sell	3,845 -479	-11%	-$1.82K	﹤0.01%	4972
2024 Q4	$10.1K	Buy	4,324 +428	+11%	+$4.16K	﹤0.01%	5379
2024 Q3	$56.9K	Buy	3,896 +2,721	+232%	+$42.2K	﹤0.01%	4981
2024 Q2	$20.1K	Buy	+1,175	New	+$25.7K	﹤0.01%	4997
2023 Q4	–	Sell	-1	Closed	-$5	–	5726
2023 Q3	$5	Buy	+1	New	+$5	﹤0.01%	5626
2021 Q2	–	Sell	-44	Closed	-$3K	–	6162
2021 Q1	$3K	Buy	+44	New	+$3.69K	﹤0.01%	5994
2019 Q1	–	Sell	-7	Closed	-$1K	–	7669
2018 Q4	$1K	Buy	+7	New	+$2.39K	﹤0.01%	7559

Other funds holding CRVO

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAM

Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

TDC

Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Citigroup's CRVO Position: Q2 2026 in Review

Citigroup opened a new position in CervoMed (CRVO) in Q2 2026: 664 shares worth $2.06K. The stake represents ﹤0.01% of the portfolio and ranks #5374 among its holdings. This is a return to the name: Citigroup previously reported a position in CRVO as recently as Q4 2025.

Citigroup first reported a position in CRVO in Q4 2018 and has held it in 11 quarters since. The position peaked at $56.9K in Q3 2024. 37 funds tracked by Wall St. Rank hold CRVO as of Q2 2026.

Citigroup held 664 shares of CervoMed worth $2.06K as of Q2 2026.
CervoMed was a new Citigroup position in Q2 2026.
CervoMed made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5374 holding.
Citigroup first reported a position in CervoMed in Q4 2018 and has held it in 11 quarters since.
Citigroup's CervoMed position peaked at $56.9K in Q3 2024.
37 funds tracked by Wall St. Rank held CervoMed as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.